Q1 2024 EPS Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Raised by Analyst

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities research analysts at Leerink Partnrs lifted their Q1 2024 earnings estimates for Marinus Pharmaceuticals in a research note issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn ($0.61) per share for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same period in the previous year, the company earned ($0.76) earnings per share.

A number of other equities research analysts also recently weighed in on MRNS. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Royal Bank of Canada restated a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday. Finally, Oppenheimer restated a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $16.07.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $1.41 on Thursday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. Marinus Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $11.26. The firm has a market cap of $77.45 million, a price-to-earnings ratio of -0.54 and a beta of 0.91. The firm’s 50-day simple moving average is $8.55 and its 200 day simple moving average is $8.40.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Eventide Asset Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 42.8% in the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock worth $36,466,000 after buying an additional 1,356,800 shares during the last quarter. Lion Point Capital LP boosted its holdings in shares of Marinus Pharmaceuticals by 14.6% in the 4th quarter. Lion Point Capital LP now owns 4,222,648 shares of the biopharmaceutical company’s stock worth $21,480,000 after buying an additional 538,026 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 245.4% in the 2nd quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company’s stock worth $42,330,000 after buying an additional 2,769,357 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock worth $41,675,000 after buying an additional 49,589 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth about $13,990,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.